ENDOART UPDATE, NEW HOPE FOR PATIENTS WHO HAVE FAILED ON HUMAN TISSUE, OR WHO ARE NOT SUITABLE FOR HUMAN TISSUE. THRU OUR EARLY COMMERCIAL EFFORTS, WE HAVE FOUND THAT ENDOART IS PRIMARILY BEING USED FOR PATIENTS WHO HAVE HAD MULTIPLE GRAFT FAILURES, PATIENTS WHO HAVE GLAUCOMA SURGERY.

ECS18

ENDOART UPDATE, NEW HOPE FOR PATIENTS WHO HAVE FAILED ON HUMAN TISSUE, OR WHO ARE NOT SUITABLE FOR HUMAN TISSUE

O. Daphna^1*

¹EyeYon, Rehovot, Israel

EyeYon is currently commercialising EndoArt in a limited market release in the EU, focusing on the most respected KOL’s who are currently generating Real World evidence, demonstrating safety, durability (we have a patients at +5 years with EndoArt) and efficacy. EyeYon is also working with the FDA and NMPA for regulatory approval in China and the USA.

This forum will allow us to share updates for both the clinical and commercial efforts with EndoArt. Endoart is primarily being used for patients who have had multiple failures on human tissue, glaucoma surgery patients (high probability of failure) and patients who do not want human tissue – people prefer synthetic material vs human tissue. EndoArt is also being used as a backup if there is an issue with the human tissue graft during surgery.